Clinical Trials

64 enrolled 21 charts

Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT02107703 2025-10-21

MONARCH 2

669 enrolled 22 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

220 enrolled 11 charts

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT04224272 2025-08-01

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

51 enrolled 10 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

874 enrolled 29 charts 1 FDA

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT02955394 2025-07-09

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

61 enrolled 12 charts

Breast Neoplasms

NCT03767335 2025-06-26

B-PRECISE-01

Phase 1 Completed

62 enrolled 18 charts

Breast Neoplasms

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Phase 1 Completed

133 enrolled 26 charts

Breast Neoplasms, Neoplasms

NCT00253422 2025-06-04

SoFEA

698 enrolled 19 charts

Breast Neoplasms

NCT01441947 2025-05-25

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

68 enrolled 11 charts

Breast Neoplasms, Neoplasm Metastasis

NCT05054374 2025-05-23

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Phase 1/2 Completed

6 enrolled 4 charts

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

36 enrolled 17 charts

Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

572 enrolled 22 charts 1 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

4 enrolled 7 charts

Breast Neoplasms

NCT02491983 2024-12-09

PARSIFAL

486 enrolled 15 charts

Breast Neoplasms

NCT02632045 2024-12-06

MAINTAIN

169 enrolled 12 charts

Breast Neoplasms

NCT03238196 2024-11-14

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Phase 1 Completed

35 enrolled 19 charts

Breast Neoplasms

NCT04060862 2024-11-08

IPATunity150

Phase 1 Terminated

20 enrolled 11 charts

Breast Neoplasms

NCT04899349 2024-10-09

EPIK-B4

2 enrolled 8 charts

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT02028507 2024-09-25

PEARL

693 enrolled 40 charts

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT02913430 2024-09-23

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

7 enrolled 13 charts

Breast Neoplasms

NCT02964507 2024-08-29

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Phase 1 Terminated

124 enrolled 23 charts

Breast Neoplasms, Neoplasms

NCT05966584 2024-08-29

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

1 enrolled 5 charts

Breast Neoplasms, Exanthema

NCT01942135 2024-04-04

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

521 enrolled 31 charts

Breast Neoplasms

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

55 enrolled 15 charts

Breast Neoplasms

NCT02536742 2024-02-26

PYTHIA

124 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02422615 2023-11-30

MONALEESA-3

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT01142401 2023-11-27

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

118 enrolled 11 charts

Breast Neoplasms

NCT04707196 2023-11-24

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Phase 4 Completed

200 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04305236 2023-06-06

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

1 enrolled 5 charts

Breast Neoplasms

NCT00921115 2023-05-19

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

42 enrolled 5 charts